Use of Selenium and Zinc Injection in the Treatment of Sepsis Patients in ICU

Efficacy and Safety of Intravenous Selenium and Zinc Supplementation on Inflammatory biomarkers of Sepsis patients in Intensive Care Unit A Randomized Controlled Trail - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/102251

Enrollment

102

Registered

2026-01-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A419- Sepsis, unspecified organism

Interventions

Intervention1: Intravenous Selenium and Zinc Supplementation: Intravenous supplementation of selenium and zinc diluted in 0.9% normal saline and administered to adult sepsis patients admitted to the I

Eligibility

Inclusion criteria

Inclusion criteria: Adults age greater than 18 years ICU admission with a confirmed diagnosis of sepsis as per Sepsis 3 criteria Willing to participate

Exclusion criteria

Exclusion criteria: End-stage liver or renal disease not related to sepsis Ongoing zinc/selenium supplementation Anemia patients Allergic to zinc or selenium Pregnancy Patients and Malignancy

Design outcomes

Primary

Measure	Time frame
Change in serum procalcitonin (PCT) levels following intravenous selenium and zinc supplementationTimepoint: Baseline Day 0 and Day 6	—

Secondary

Measure	Time frame
Change in C-reactive protein (CRP) Change in lymphocyte count Change in serum lactate levels Length of ICU stay 28-day in-hospital mortalityTimepoint: Baseline Day 0 and Day 6	—

Countries

India

Contacts

Public ContactDr R Venkatraman

SRM Institute of Science and Technology

venkatrr@srmist.edu.in9843845009

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026